| DYNC1H1 — Dynein Cytoplasmic 1 Heavy Chain 1 | |
|---|---|
| Symbol | DYNC1H1 |
| Full Name | Dynein Cytoplasmic 1 Heavy Chain 1 |
| Chromosome | 14q32.31 |
| NCBI Gene | 1778 |
| Ensembl | ENSG00000197958 |
| OMIM | 600112 |
| UniProt | Q14204 |
| Diseases | Spinal Muscular Atrophy, Cortical Malformations, Charcot-Marie-Tooth Disease, Hereditary Spastic Paraplegia |
| Expression | Motor neurons, Cerebral cortex, Widespread |
| Key Mutations | |
| H3822P R3344Q I584L K3241T T4588M |
|
Dync1H1 — Dynein Cytoplasmic 1 Heavy Chain 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DYNC1H1 (Dynein Cytoplasmic 1 Heavy Chain 1) is a large gene located on chromosome 14q32.31 that encodes the heavy chain subunit of the cytoplasmic dynein 1 motor complex—the primary motor for retrograde axonal transport along microtubules. Heterozygous mutations in DYNC1H1 cause a spectrum of autosomal dominant neurological disorders including spinal muscular atrophy with lower extremity predominance (SMA-LED), cortical malformations with intellectual disability, axonal Charcot-Marie-Tooth disease (CMT2O), and hereditary spastic paraplegia (Harms et al., 2012; Weedon et al., 2011). The gene is catalogued as NCBI Gene ID 1778 and OMIM 600112.
DYNC1H1 encodes the 532-kDa heavy chain of cytoplasmic dynein 1, the major minus-end-directed microtubule motor protein in mammalian cells. Dynein transports diverse cargo including mitochondria, endosomes, lysosomes, signaling endosomes, and mRNA granules from the distal axon back toward the cell body (retrograde transport). The heavy chain contains an N-terminal tail domain (cargo binding and dynactin interaction), a linker domain, a ring of six AAA+ ATPase domains that generate force, and a microtubule-binding domain at the tip of a coiled-coil stalk (Roberts et al., 2013).
Motor neurons are particularly vulnerable to dynein dysfunction due to their exceptionally long axons (up to 1 meter in humans). Dynein-mediated retrograde transport is essential for:
During brain development, dynein is critical for neuronal migration in the cerebral cortex. DYNC1H1 mutations that impair dynein function during development cause cortical malformations including pachygyria, polymicrogyria, and neuronal heterotopia (Poirier et al., 2013).
DYNC1H1 is ubiquitously expressed, with particularly high levels in motor neurons, cerebral cortex, and developing brain. Expression data is available from the Allen Human Brain Atlas.
DYNC1H1 mutations cause a clinical-phenotype continuum (Amabile et al., 2020):
The most common DYNC1H1-associated phenotype. Presents with congenital or childhood-onset lower limb wasting and weakness, frequently associated with cognitive impairment. Clinical severity ranges from generalized arthrogryposis and inability to ambulate to mild lower limb weakness (Harms et al., 2012). Mutations in both the tail and motor domains of DYNC1H1 can cause SMA-LED.
Mutations affecting dynein's role in neuronal migration cause malformations of cortical development (MCD), including pachygyria, polymicrogyria, and periventricular heterotopia, often accompanied by severe intellectual disability and epilepsy (Poirier et al., 2013).
Peripheral motor and sensory neuropathy caused by DYNC1H1 mutations affecting axonal transport in peripheral nerves.
A recent study identified a rare missense variant (p.Thr4588Met) causing autosomal dominant complex HSP in a Chinese family, expanding the clinical spectrum (Qu et al., 2025).
| Mutation | Domain | Phenotype |
|---|---|---|
| H3822P | Motor (AAA4) | SMA-LED with cognitive impairment |
| R3344Q | Motor (AAA3) | SMA-LED |
| I584L | Tail | SMA-LED; destabilizes dynein complex and decreases microtubule affinity (Ori-McKenney et al., 2010) |
| K3241T | Motor (AAA3) | SMA-LED with cortical malformations |
| T4588M | Motor (AAA6) | Hereditary spastic paraplegia (Qu et al., 2025) |
The study of Dync1H1 — Dynein Cytoplasmic 1 Heavy Chain 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Page expanded by NeuroWiki quality review. Last updated: 2026-02-27.